Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWDiscover new patient engagement possibilities with IQVIA insights, expertise, and technology-driven solutions.
Patient Engagement OverviewExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSPD1/PD-L1-targeted monoclonal antibodies or mAbs have emerged as the backbone of treatment for numerous types of cancer. But, over the past few years, it is obvious there are more attention on how to further maximize these inhibitors to potentially help more patients in need. Since the first PD-1 inhibitor pembrolizumab or Keytruda® by brand name was approved by the U.S. Food and Drug Administration (FDA) in 2014, PD-1/PD-L1 inhibitors have quickly become the center of immuno-oncology drug development, with a total of 9 treatments on the market globally. And, as treatments show promise and focus from researchers, sponsors, and patients grow, the industry has an opportunity to learn more and help elevate research around various disciplines in the space.
To better understand the trends and areas of focus in clinical development around this class of treatments over the last few years, IQVIA partnered with the Cancer Research Institute, a US non-profit cancer research organization, to analyze the landscape, gathering insights from investigators, key opinion leaders (KOL), and existing clinical learnings from across the US, Europe, and Asia. The findings were published in Nature Reviews Drug Discovery. To learn more, read Trends in Clinical Development for PD-1/PD-L1 Inhibitors.
Since 2006, nearly 3,000 trials have launched and are still active (as of 2019) examining PD-1/PD-L1 mAbs alone or in combination with other treatments. Of note, 76% of the active trials focus on testing combination therapies of these inhibitors with other cancer therapies, including targeted therapies, chemotherapies, radiotherapies, and more. This priority focus has resulted in:
Click image above to download the article and view graph
The industry already has a breadth of data showing how these therapies are beneficial to treat major types of cancer such as melanoma, breast cancer, and more. With the potential to expand how combination strategies can be utilized to treat rare forms of cancer or serve as tumor-agnostic therapy options regardless of cancer type, survey findings show that PD-1/PD-L1 trial sizes are getting smaller as well. These smaller targeted trials are focused on patient populations requiring biomarker enrichment, to improve patient response—adding more growth and complexity to the oncology trial landscape.
To ensure the right patients are identified, recruited, and enrolled in the right trials, innovative solutions need to meet the demands and challenges of novel research around PD1/PD-L1 combination therapy strategies.
Virtual trial solutions
According to the analysis, China has the highest patient recruitment rate for PD-1/PD-L1 clinical trials, especially as patients with cancer there do not already receive these mAbs as a form of treatment. In markets such as the US and western Europe where recruitment is more challenging, incorporating virtual trial elements can help improve and accelerate the process and has been increasingly adopted during the COVID-19 pandemic. By working through virtual elements such as telemedicine, providing closer locations for assessment visits, direct-to-home medication delivery, and more, the burden placed on patients can be reduced, which is critical for those living with cancer and caregivers as well. And, patients can participate in trials from around the globe—helping researchers overcome challenges of recruitment and engagement.
Enhancing patient-to-trial matching
Patient identification and recruitment for smaller, targeted trials can be cost and time-intensive. In many cases, identifying and recruiting the right patients for individual trials takes several months to search and vet thousands of patient records. Given the rising trend to study PD1/PD-L1 based combination therapies in rare cancer populations, there's a need for new approaches such as leveraging real world insights to help identify these rare patients in less time.
We work closely with our molecular profiling partners to narrow down the pool and identify patients with the appropriate tumor profiles, which significantly reduces prescreening time and efforts. In some cases, we’re able to reduce prescreening processes by months. When time is of the essence, this is extremely valuable to sponsors and patients who are waiting for viable treatments.
Bringing data scientists into the site selection process helps too. We can identify the location of target patient populations and then activate sites nearby. For trials examining tumor agnostic therapies, biomarkers help us identify the right patients. Study teams can go as far as to pinpoint sites that are using next generation sequencing DNA technology as part of their standard of care, as they may be more likely to have patients who qualify for a tumor agnostic trial.
Shifting the paradigm: early engagement
As trends continue to evolve around PD-1/PD-L1 inhibitor use in combination with targeted therapies, one thing remains certain: patients with cancer cannot afford to wait for new treatments. As the industry shifts focus from major types of cancer to niche indications, smaller trials targeting rare mutations face more competition for patients. Payer reimbursement programs may need to adapt as well. It is important that sponsors engage all critical stakeholders early in the oncology clinical development process so innovative approaches can evolve with the trends and life changing therapies reach patients who need them quicker.
To learn more, read Trends in Clinical Development for PD-1/PD-L1 Inhibitors in Nature Reviews Drug Discovery.